a method of killing or preventing the occurrence of parasitic worms in an animal hosting or susceptible to said worms comprising the administration to said animal of a therapeutic or prophylactic dosage of dioxapyrrolomycin . dioxapyrrolomycin is particularly effective against the following parasitic worms : dictyocaulus , haemonchus , trichostrongylus , ostertagia , nematodirus , cooperia , bunostomum , oesophagostomum , chabertia , strongyloides , trichuris , fasciola , dicrocoelium , enterobius , ascaris , toxascaris , toxocara , ascaridia , capillaria , heterakis , ancylostoma , uncinaria , onchocerca , taenia , moniezia , dipylidium , metastrongylus , hyostrongylus , and strongylus . these worms most often occur in animals , such as sheep , swine , cattle , goats , dogs , cats , horses , poultry and man . an anthelmintic composition for administration to animals which comprises an effective anthelmintic amount of dioxapyrrolomycin . such a composition is useful in animals , such as sheep , swine , cattle , goats , dogs , cats , horses , poultry and man . in the process for producing dioxapyrrolomycin from a streptomyces sp ., the improvement which comprises : the use of a culture medium comprising from about 10 to about 30 mg of starch , from about 10 to about 30 g of solulys , from about 2 to about 8 g of meat extract , and from about 4 to about 6 g of sodium chloride , to culture the streptomyces sp . the preferred ingredients for the medium are the following : difco soluble starch 20 g / l ; solulys 20 g ; beef extract 4 g ; nacl 5 g ; tap water , quantity sufficient ( qs ) 1 liter ; ph adjusted to 7 . 2 ( koh ). this process may be further improved by the addition of the resin xad - 2 to the medium . pharmaceutically acceptable refers to those properties and / or substances which are acceptable to the patient from a pharmacological - toxicological point of view and to the manufacturing pharmaceutical chemist from a physical - chemical point of view regarding composition , formulation , stability , patient acceptance and bioavailability . the present invention includes the anthelmintic use and anthelmintic compositions of dioxapyrrolomycin . its structure is shown as formula i in the formula chart below . dioxapyrrolomycin is a known compound and may be prepared by the methods described in g . t . carter , et at ., j . antibio . 40 : 233 ( 1987 ); h . nakamara , et at . j . antibio . 40 : 899 ( 1987 ). however , the present invention provides an improvement in the process for the preparation of dioxapyrrolomycin . in g . t . carter , et al ., j . antibio . 40 : 233 ( 1987 ), the medium employed in the tank fermentation consisted of molasses 20 g / l ; dextrin 10 g ; soy peptone 10 g ; caco 3 1 g ; ph adjusted to 7 . 2 ( koh ). the medium of the present invention employs cbs - 10 which preferably comprises difco soluble starch 20 g / l ; solulys 20 g ; beef extract 4 g ; nacl 5 g ; tap water , quantity sufficient ( qs ) 1 l ; ph adjusted to 7 . 2 ( koh ). these ingredients are commercially available . the amounts of ingredients are approximate and may be varied as appropriate by one of ordinary skill in the art . corn steep liquor or spray dried lard water may be used in place of solulys . the use of this medium more than doubled the yield of dioxapyrrolomycin . the use of this medium plus the resin xad - 2 , which is commercially available , not only doubled the yield of dioxapyrrolomycin , but also produced twice as pure compound , as did the medium alone . other such neutral resins may be used , but xad - 2 is preferred . thus , in producing dioxapyrrolomycin for the present invention , the use of a neutral resin ( xad - 2 ) as a titer enhancer was successfully employed . it was found that the addition of 50 g / l of xad - 2 in tank fermentations , more than doubled the amount of crude fermentation products that are extractable than when literature procedures alone are used . this increased product yield increases the amount of recoverable dioxapyrrolomycin even though the production of dioxapyrrolomycin has not increased relative to the other fermentation products . the biological assays used to examine this compound included in vitro effects on the free - living nematode caenorhabditis elegans , ability to clear target nematodes ( haemonchus contortus and trichostrongylus colubriformis ) from experimentally infected jirds , and clearance of haemonchus contortus from monospecifically infected lambs , as described in more detail below . dioxapyrrolomycin is active in the c . elegans in vitro assay at 0 . 825 ppm . table i shows results obtained for dioxapyrrolomycin against h . contortus and a second target parasite , t . colubriformis in the jird model . dioxapyrrolomycin exhibited strong activity (≧ 90 . 9 % clearance at 0 . 33 mg / jird = 8 . 25 mg / kg ; 96 . 4 % clearance at 0 . 037 mg / jird = 0 . 925 mg / kg ) against this parasite . it also is worth noting that although dioxapyrrolomycin is not highly active against t . colubriformis , it has a hint of activity ( 41 . 5 % clearance at 0 . 33 mg / jird = 8 . 25 mg / kg ) against this parasite . table ii shows results obtained for dioxapyrrolomycin in sheep against h . contortus ( monospecific , experimental infections ). dioxapyrrolomycin exhibited potent activity ( 92 . 2 % clearance of the worms at 1 . 56 mg / kg ). having shown potent activity against h . contortus in sheep , dioxapyrrolomycin was examined for cross - resistance to the three major classes of broad - spectrum anthelmintics ( ivermectin , levamisole , and benzimidazoles ) using jirds infected with resistant strains of h . contortus . the data presented in table iii shows that dioxapyrrolomycin is equally efficacious against the resistant and nonresistant strains studied and hence is not cross - resistant to the major broad - spectrum anthelmintics . dioxapyrrolomycin does , however , exhibit cross - resistance to closantel , a narrow - spectrum anthelmintic used in controlling h . contortus . in vitro , the dioxapyrrolomycin dose required to affect a closantel - resistant strain of h . contortus is approximately seventeen times that required for the susceptible strain . in summary , dioxapyrrolomycin has activity of potential utility against the important ruminant parasite , h . contortus . dioxapyrrolomycin appears to have some , albeit very weak , activity against a second ruminant parasite , t . colubriformis . lack of cross - resistance with the three ( 3 ) major classes of broad - spectrum anthelmintics , but cross - resistance with the narrow - spectrum drug closantel , has been demonstrated for dioxapyrrolomycin . therefore , dioxapyrrolomycin is effective against worms , particularly parasitic worms of warm - blooded animals and more particularly helminth parasites in ovines ( sheep ) and bovines ( cattle ). dioxapyrrolomycin of formula i can be used as the pure compound or as a mixture of pure compound , but for practical reasons , the compound is preferably formulated as an anthelmintic composition and administered as a single or multiple dose , alone or in combination with other anthelmintics ( e . g . avermectins , benzimidazoles , levamisole , praziquantel , etc .). for example , aqueous or oil suspensions can be administered orally , or the compound can be formulated with a solid carrier for feeding . furthermore , an oil suspension can be converted into an aqueous emulsion by mixing with water and injecting the emulsion intramuscularly , subcutaneously or into the peritoneal cavity . in addition , dioxapyrrolomycin ( which hereafter may be referred to as the &# 34 ; active compound &# 34 ;) can be administered topically to the animal in a conventional pour - on formula . pure active compound , mixtures of the active compound , or combinations thereof with a solid carrier can be administered in the animal &# 39 ; s food , or administered in the form of tablets , pills , boluses , wafers , pastes , and other conventional unit dosage forms , as well as sustained / controlled release dosage forms which deliver the active compound over an extended period of days , weeks or months . all of these various forms of the active compound of this invention can be prepared using physiologically acceptable carriers and known methods of formulation and manufacture . representative solid carriers conveniently available and satisfactory for physiologically acceptable , unit dosage formulations include corn starch , powdered lactose , powdered sucrose , talc , stearic acid , magnesium stearate , finely divided bentonite , and the like . the active compound can be mixed with a carrier in varying proportions from , for example , about 0 . 001 percent by weight in animal feed to about 90 or 95 percent or more in a pill or capsule . in the latter form , one might use no more carrier than sufficient to bind the particles of active compound . in general , the active compound can be formulated in stable powders or granules for mixing in an amount of feed for a single feeding or enough feed for one day and thus obtain therapeutic efficacy without complication . it is the prepared and stored feeds or feed premixes that require care . a recommended practice is to coat a granular formulation to protect and preserve the active compound . a prepared hog - feed containing about 0 . 02 percent of the active compound will provide a dosage of about 10 mg per kg body weight for each 100 lb pig in its daily ration . a solid diluent carrier need not be a homogeneous entity , but mixtures of different diluent carriers can include small proportions of adjuvants such as water ; alcohols ; protein solutions and suspensions like skimmed milk ; edible oils ; solutions , e . g ., syrups ; and organic adjuvants such as propylene glycols , sorbitol , glycerol , diethyl carbonate , and the like . the solid carrier formulations of the active compound are conveniently prepared in unit dosage forms , to facilitate administration to animals . accordingly , several large boluses ( about 2 g weight ) amounting to about 4 . 1 g of active compound would be required for a single dosage to a 900 lb horse at a dosage rate of 10 mg / kg of body weight . similarly , a 60 lb lamb at a dosage rate of 10 mg / kg of body weight would require a pill , capsule , or bolus containing about 0 . 3 g of active compound . a small dog , on the other hand , weighing about 20 lbs . would require a total dosage of about 90 mg at a dosage rate of 10 mg / kg of body weight . the solid , unit dosage forms can be conveniently prepared in various sizes and concentrations of active compound , to accomodate treatment of the various sizes of animals that are parasitized by worms . liquid formulations can also be used . representative liquid formulations include aqueous ( including isotonic saline ) suspensions , oil solutions and suspensions , and oil in water emulsions . aqueous suspensions are obtained by dispersing the active compound in water , preferably including a suitable surface - active dispersing agent such as cationic , anionic , or non - ionic surface - active agents . representative suitable ones are polyoxyalkylene derivatives of fatty alcohols and of sorbitan esters , and glycerol and sorbitan esters of fatty acids . various dispersing or suspending agents can be included and representative ones are synthetic and natural gums , tragacanth , acacia , alginate , dextran , gelatin , sodium carboxymethylcellulose , methylcellulose , sodium polyvinylpyrrolidone , and the like . the proportion of the active compound in the aqueous suspensions of the invention can vary from about 1 percent to about 20 percent or more . oil solutions are prepared by mixing the active compound and an oil , e . g . an edible oil such as cottonseed oil , peanut oil , coconut oil , modified soybean oil , and sesame oil . usually , solubility in oil will be limited and oil suspensions can be prepared by mixing additional finely divided active compound in the oil . oil in water emulsions are prepared by mixing and dispersing an oil solution or suspension of the active compound in water preferably aided by surface - active agents and dispersing or suspending agents as indicated above . in general , the formulations of this invention are administered to animals so as to achieve therapeutic or prophylactic levels of the active compound . at present , it is known that doses of 1 . 56 to 12 . 5 mg / kg of body weight in sheep of dioxapyrrolomycin will effectively combat h . contortus . effective therapeutic and prophylactic dosages are contemplated in the range of about 2 to about 20 mg / kg of body weight . in other animals , and for other kinds of parasitic worms , definitive dosages can be proposed . contemplated are dosage rates of about 1 mg to about 20 mg / kg of body weight . a preferred , contemplated range of dosage rates is from about 5 mg to about 10 mg / kg of body weight . in this regard , it should be noted that the concentration of active compound in the formulation selected for administration is in many situations not critical . one can administer a larger quantity of a formulation having a relatively low concentration and achieve the same therapeutic or prophylactic dosage as a relatively small quantity of a relatively more concentrated formulation . more frequent small dosages will likewise give results comparable to one large dose . one can also administer a sustained release dosage system ( protracted delivery formulation ) so as to provide therapeutic and / or prophylactic dosage amounts over an extended period . unit dosage forms in accordance with this invention can have anywhere from less than 1 mg to 50 g of active compound per unit . although dioxapyrrolomycin will find its primary use in the treatment and / or prevention of helminth parasitisms in domesticated animals such as sheep , cattle , horses , dogs , swine , goats and poultry , it is also effective in treatment that occurs in other warm blooded animals , including humans . the optimum amount to be employed for best results will , of course , depend upon species of animal to be treated , the regimen treatment and the type and severity of helminth infection . generally good results are obtained with dioxapyrrolomycin by the oral or parenteral route of administration of about 1 to 10 mg / kg of animal body weight ( such total dose being given at one time , in a protracted manner or in divided doses over a short period of time such as 1 - 4 days ). the technique for administering these materials to animals are known to those skilled in the veterinary and medical fields . it is contemplated that dioxapyrrolomycin can be used to treat various helminth diseases in humans , including those caused by ascaris , enterobius , ancylostoma , trichuris , strongyloides , fasciola , taenia , and / or onchocerca or other filariae at a dose of from 1 to 20 mg / kg of body weight upon oral and / or parenteral administration . the following detailed examples / procedures describe the biological testing and production of dioxapyrrolomycin and are to be construed as merely illustrative , and not limitations of the preceding disclosure in any way whatsoever . those skilled in the art will promptly recognize appropriate variations from the procedures . the free - living nematode c . elegans in vitro assay has been described extensively in the literature , for example , k . g . simpkin and g . c . coles , j . chem . tech . biotechnol ., 31 : 66 - 69 ( 1981 ). dioxapyrrolomycin is active in the c . elegans assay at 0 . 825 ppm . this in vivo assay utilizes jirds infected with two important target parasites of ruminants , h . contortus and t . colubriformis ( anthelmintic - sensitive or - resistant worms can be used ). initially , activity is assessed only against h . contortus as described in g . a . conder et . al ., j . parasitol . 76 : 168 - 170 ( 1990 ), while follow - up studies examine activity against both species of parasites using the techniques outlined in g . a . conder et at ., j . parsitol . 77 : 168 - 170 ( 1991 ). table i shows results obtained for dioxapyrrolomycin in the jird model . purpose bred , helminth - free lambs are procured . upon ardvai , the lambs are treated with ivermectin ( 0 . 2 mg / kg , subcutaneously ), vaccinated for sore mouth , and placed in a single , community pen . three weeks later each lamb is treated with levamisole hydrochloride ( 8 . 0 mg / kg per os ). two weeks after treatment with levamisole , all lambs are inoculated per os with -- 7 , 500 infective larvae of h . contortus . rectal fecal samples are taken from each lamb 1 to 3 days prior to infection and these are examined using the double centrifugation technique to verify that the animals are free of trichostrongyles prior to infection . on day 32 - 34 postinoculation ( pi ), a rectal fecal sample from each lamb is examined again using the mcmaster counting chamber technique to verify infection ; those animals which do not exhibit suitable infection are dropped from the study . remaining lambs are treated per os on day 35 pi ; 4 - 5 animals receive vehicle only . prior to administration , test materials are prepared in a manner suitable for the substance being examined . all lambs are monitored for toxic signs following treatment . lambs are killed 7 days after treatment ( day 42 pi ), and the abomasum is ligated and removed from each animal . each abomasum is opened longitudinally and the contents rinsed into an 80 mesh sieve . sieve contents are collected in individual containers and fixed in formol - alcohol . later each sample is transferred to a 1 , 000 ml graduated cylinder and the volume brought to 400 - 1000 ml with tap water . the total number of worms in a 10 % aliquot is determined . if no worms are found in the 10 % aliquot , the entire sample is examined . total worm number / lamb and percentage clearance for each treatment are calculated . percentage clearance is determined according to the following formula : percentage clearance =[( mean number of worms recovered from vehicle control lambs -- number of worms recovered from treated lamb )/ mean number of worms recovered from vehicle control lambs ]× 100 . a substance is considered highly active if its clearance is ≧ 90 % and moderately active if its clearance is ≧ 70 but & lt ; 90 %. table ii shows results obtained for dioxapyrrolomycin in sheep against h . contortus ( monospecific , experimental infections ). streptomyces sp . 90413 ( strain number in upjohn culture collection , 90413 , uc ® 11065 , the upjohn co ., kalamazoo , mich .) is isolated from michigan soil and maintained as frozen agar plugs of vegetative growth in a liquid nitrogen vapor phase . it is believed that other known dioxapyrrolomycin - producing streptomyces sp ., such as those identified in g . t . carter , et al ., j . antibio . 40 : 233 ( 1987 ), and h . nakamara , et at ., j . antiobio . 40 : 899 ( 1987 ), would be suitable substitutes for the above species in the process of the present example . primary fermentations in medium cbs 10 are carded out in 100 ml volumes in shaken flasks . shake flask fermentations are run for 72 hours in 100 ml volumes in 500 ml wide - mouth flasks at 28 ° c . ( 250 rpm , 1 . 5 inch throw ). shake flask pools ( 2 and 3 liter ) are inoculated from 100 mi seed shake flask cultures ( medium gs - 7 : 25 g / l cerelose , 25 g / l pharmamedia , ph = 7 . 2 with nh 4 oh , autoclaved 30 minutes ) at a 5 % ( v / v ) rate . the organism is inoculated into medium gs - 7 . the inoculated 100 ml volumes of gs - 7 are fermented for 72 hours as described above . the mature seed cultures are used as the source of inoculum ( 5 % seed rate ) for the fermentation medium ( cbs 10 containing xad - 2 ). cbs - 10 is composed of difco soluble starch 20 g ; solulys , 20 g ; beef extract 4 g ; nacl 5 g ; and tap water , quantity sufficient ( qs ) 11 . neutral resin ( xad - 2 ) is incorporated into cbs 10 before autoclaving in flasks at a final concentration of 60 g / l . in tank fermentations , sterile xad - 2 is added 2 - 3 hours post inoculation at a final concentration of 50 g / l . the ph of the fermentation medium is adjusted to 7 . 2 using koh before autoclaving ( 30 min / flask , 90 min / tank ). inoculated flask fermentations are employed in the manner described for gs - 7 above for four days of fermentation . inoculated 10 l tank fermentations ( labraferm ) are stirred at 250 rpm at 28 ° c . with an air flow rate of 6 - 7 l / min for 4 - 5 days of fermentation . assay samples from shake flask fermentations ( 1 . 5 ml ) are centrifuged and the clear supernatants are transferred to 1 . 2 ml microtubes . samples are assayed for activity as described in the examples above . filter whole beer at harvest ph ( celaton fw - 40 filter aid may be used if desired ). the clear filtrate may be discarded . process the mycelial cake as described below . the xad - 2 resin remains in the mycelial cake during filtration and should be processed as part of the cake . 1 . stir mycelial cake three times with 1 / 6 original beer volumes of acetone each time ( acetone - 1 ,- 2 ,- 3 ). combine acetone extracts 1 , 2 & amp ; 3 and process as described below . 1 . add 1 / 2 pool volume of methylene chloride to the acetone pool . separate organic phase ( lower ) from the aqueous acetone phase ( upper ). aqueous phase may be discarded . dry mecl 2 / acetone organic phase over na 2 so 4 and concentrate to an oil in vacuo ( preparation a ). preparation a should then be fractionated by silica gel column chromatography as described below . 1 . an open silica gel ( 70 - 230 mesh ) column * is poured and equilibrated in two bed volumes of n - hexane . preparation a from above is absorbed onto 2 times its weight of silica gel and loaded onto the head of the column . 2 . the silica gel column is then eluted ** in the following manner : start : 2 - bed volumes n - hexane 4 - bed volumes 85 hexane : 15 etoac 3 . silica column pools are collected in bed volume aliquots as described below : 4 . the above silica column pools b - f are then concentrated to dryness in vacuo . pool d will contain the majority of dioxapyrrolomycin and will be referred to as preparation b . pools c and e may contain small quantities of dioxapyrrolomycin . verification of silica pool compositions may be done by the analytical hplc procedure described below . analytical hplc of preparation b 1 . analytical hplc for sample analysis and peak identification was performed on a hewlett packard ( hp ) 1090a with diode array detector ( dad ) and hp pc work station . separation was performed on an hp 2 . 1 mm × 200 mm ods ( hypersil ) rp ( 5 um ) column preceded by an hp ods guard column . elution was achieved with isocratic 65 % acn : 35 % nh 4 oac ( ph = 4 . 0 ) for 5 . 0 minutes followed by a 20 minute linear gradient to 100 % acn . column temperature was maintained at 65 ° c . and column eluant was monitored by uv detection @ 240 nm . mobile phase flow rate was maintained at 0 . 5 ml / min throughout the entire separation . sample injections of 1 . 0 - 25 . 0 mcl were performed automatically by the hp 1090a hplc . the relative retention time of dioxapyrrolomycin under these analytical hplc parameters is 1 . 4 minutes and peak identification is verified by dioxapyrrolomycin &# 39 ; s characteristic uv spectrum recorded by the dad . once the composition of preparation b has been verified by analytical hplc , the final recovery of pure dioxapyrrolomycin from preparation b was carried out by preparative hplc as described below . preparative hplc for purification of dioxapyrrolomycin from preparation b was performed on a waters prep lc 3000 with a variable wavelength uv / vis detector and waters 745b integrator . separation was performed on three waters radial pak c - 18 ( 25 × 100 mm ) columns in series with a waters 25 × 10 mm radial pak c - 18 guard column . elution was achieved with isocratic 60 % acn : 40 % nh 4 oac ( ph = 4 . 0 ) for 25 minutes . column was maintained at ambient temperature with column eluant monitored by uv detection @ 254 nm . mobile phase flow rate was maintained at 34 . 2 ml / min throughout the entire separation . sample injections were pumped directly onto the head of the column with maxima injection volumes of 50 . 0 ml . the retention time of dioxapyrrolomycin under these preparative hplc parameters ranges between 9 . 00 and 12 . 00 minutes depending on sample load . baseline resolution of dioxapyrrolomycin is achievable under these parameters ; however , purity of preparative hplc fractions should be checked by analytical hplc analysis prior to pooling of preparative fractions . excess nh 4 oac buffer from the preparative hplc procedure was removed from the sample by absorbing the dioxapyrrolomycin onto hp - 20 resin and washing of the resin with water . the dioxapyrrolomycin was then recovered from the resin by extraction with meoh . crystalline dioxapyrrolomycin ( preparation c ) is the resulting product of this final purification stage . verification of the structure of preparation c , was then accomplished by the spectroscopic and analytical analysis described below . preparation c ( 1 ) was obtained as fine yellow needles . the uv spectrum of 1 suggested 1 is structurally related to pyrrolomycins . computer search of the ir spectrum of 1 against the spectrum library identified dioxapyrrolomycin as the most likely structure . comparison of these spectra , with published uv and ir spectrum of dioxapyrrolomycin showed that they are virtually superimposable . the elemental analysis results ( 37 . 4 % c , 1 . 5 % h , 7 . 0 % n , 36 . 5 % cl ) of 1 are consistent the molecular formula of dioxapyrrolomycin ( c 12 h 6 n 2 o 4 cl 4 which predicts 37 . 5 % c , 1 . 6 % h , 7 . 35 n , 37 . 0 % cl ). fab - ms spectrum of 1 displayed a weak ion cluster ( m / e = 382 , 384 , 386 ), expected for the ( m + h ) + ions of dioxapyrrolomycin . the most intense peaks at 306 , 308 , and 310 represent the loss of one nitro and one formaldehyde ( m -- no 2 -- ch 2 o ) from molecular ions . the hmr spectrum ( obtained in cdcl3 ) of 1 displayed only one exchangeable proton at 9 . 14 ppm , due to the pyrrole proton . the higher field position of this proton , compared to the similar situated proton in pyrrolomycin c , is attributed to the absence of a neighboring carbonyl group . a total of five non - exchangeable protons were detected between 5 and 8 ppm region . the ab quartet ( 5 . 58 , 5 . 37 ppm , j = 6 . 2 hz ) is consistent with the presence of a mythylenedioxy group . the sharp singlet ( 6 . 85 ppm ) is consistent with the presence of a carbinol proton sandwiched between two aromatic systems . the two long - ranged coupled protons at 7 . 31 and 6 . 88 ppm ( j = 2 . 1 hz ) are consistent with the presence of a 1 , 2 , 3 , 5 tetrasubstituted phenyl group . again , the relative deshielding of these two protons , compared to pyrrolomycin c , is attributed to the reduction of the carbonyl group to the methyleneoxy functionality . the cmr signals of 1 ( 75 mhz , deuterated meoh ) are as follows : δ 146 . 2 ( s ), 131 . 5 ( s ), 130 . 5 ( d ), 130 . 4 ( s ), 127 . 3 ( s ), 126 . 1 ( d ), 125 . 5 ( s ), 124 . 0 ( s ), 117 . 5 ( s ), 106 . 0 ( s ), 92 . 3 ( t ) and 70 . 4 ( d ). while all of above signals ( chemical shift and multiplicities ) agree well with the structure of dioxapyrrolomycin , small differences were observed between these and the reported values ( 8 ) ( obtained in cdcl3 ) as a result of solvent effects . since the structure of dioxapyrrolomycin contains an optical center , ord of 1 was obtained ( c = 2 . 23 , meoh ) to determine the chirality of 1 . the result (- 77 °) is in fair agreement with the reported value (- 88 °) of dioxapyrrolomycin therefore indicated that 1 has same absolute configurations as that of dioxapyrrolomycin . table i__________________________________________________________________________percentage clearance of haemonchus contortus and trichostrongyluscolubriformisfrom jirds inoculated per os with ˜ 1 , 000 exsheathed , infectivelarvae of each parasite , treated per os with dioxapyrrolomycin on day 10 postinoculation ( pi ) andnecropsied onday 13 postinoculation . compound dose n ( survived percentage clearance ( reference ) purity ( mg / jird ) to necropsy ) h . contortus t . colubriformis__________________________________________________________________________dioxapyrrolomycin ˜ 100 % 0 . 33 3 ( 1 ) 90 . 9 41 . 5 0 . 33 3 ( 3 ) 100 41 . 5 0 . 11 3 ( 3 ) 100 0 0 . 037 3 ( 3 ) 96 . 4 17 . 2 0 . 012 3 ( 3 ) 45 . 8 48 . 8__________________________________________________________________________ table ii______________________________________percentage clearance of haemonchus contortus from lambs mono - specifically inoculated per os with ˜ 7 , 500 infective larvae of theparasite , treated per os with dioxapyrrolomycin on day 35 post - inoculation ( pi ), and necropsied on day 42 pi . compound dose percentage ( reference ) purity ( mg / kg ) clearance______________________________________dioxapyrrolomycin ˜ 100 % 12 . 5 100 6 . 25 99 . 9 3 . 125 99 . 7 ˜ 100 % 3 . 125 99 . 9 1 . 56 92 . 2 0 . 78 44 . 0______________________________________ table iii__________________________________________________________________________percentage clearance of susceptible , levamisole / benzimidazole - resistant , orivermectin - resistant haemonchus contortus from jirds inoculated per oswith ˜ 1 , 000 exsheathed , infective larvae of a particular strain of theparasite , treated peros with dioxapyrrolomycin , levamisole hydrochloride , albendazole , orivermectinon day 10 postinoculation ( pi ), and necropsied on day 13 pi . percentage clearance levamisole / compound dose benzimidazole ivermectin ( reference ) purity ( mg / jird ) susceptible resistant resistant__________________________________________________________________________dioxapyrrolomycin 95 %* 0 . 11 95 . 8 98 . 6 92 . 7levamisole hydro - 0 . 4 ˜ 95 . 0 51 . 7 96 . 4chloridealbendazole 0 . 075 ˜ 95 . 0 36 . 2 n . d . ivermectin 0 . 005 ˜ 95 . 0 98 . 6 18 . 7__________________________________________________________________________ * pyrrolomycin c makes up the majority of the remainder . n . d . = not done . ## str2 ##
this invention concerns a method for killing internal parasites , especially nematodes , trematodes and cestodes affecting warm blooded animals such as sheep , cattle , swine , goats , dogs , cats , horses and humans as well as poultry by administering an effective amount of dioxapyrrolomycin of the formula i . anthelmintic compositions of dioxapyrrolomycin and an improvement in the process of preparation of dioxapyrrolomycin are also provided . ## str1 ##